Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
2.
J Dtsch Dermatol Ges ; 19(6): 852-862, 2021 06.
Article in English | MEDLINE | ID: mdl-33890389

ABSTRACT

BACKGROUND: Patients with stage IIC malignant melanoma are recommended to undergo cross-sectional imaging for initial staging. PET/CT is superior to other methods regarding its diagnostic accuracy of the tumor spread in stage III. So far there is no meaningful data on the nationwide availability, usage and cost recovery of this imaging technique. PATIENTS AND METHODS: Questionnaires on the healthcare situation in 2018 were sent to all German dermatology clinics and PET/CT centers in March and April 2019. RESULTS: 61.2 % of the dermatology clinics (71/115) and 48.2 % of the PET/CT centers (77/160) took part in the survey. A total of 22,645 patients with malignant melanoma were seen in these clinics in 2018. 16.8 % of the patients with stage IIC melanoma received a PET/CT for primary staging. The costs of this examination were covered for all statutory and privately insured patients in 40 % and 68 % of dermatology clinics (20/50 and 34/50), respectively. 68.0 % (34/50) of all dermatology clinics reported relevant changes of treatment according to PET/CT findings. Long examination periods by the health insurance companies and the time required to submit the application were the most common reasons for dermatology clinics to reject a request for PET/CT. Relevant incidental findings were reported in 90.2 % (47/51) of all PET/CT centers. CONCLUSIONS: There are clear differences in the nationwide availability and cost coverage of PET/CT in primary staging for stage IIC melanoma. For these reasons, a two-tiered healthcare system may be assumed.


Subject(s)
Melanoma , Skin Neoplasms , Delivery of Health Care , Fluorodeoxyglucose F18 , Humans , Melanoma/diagnostic imaging , Melanoma/pathology , Neoplasm Staging , Positron Emission Tomography Computed Tomography , Positron-Emission Tomography , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/pathology , Tomography, X-Ray Computed
3.
J Dtsch Dermatol Ges ; 19(1): 31-36, 2021 Jan.
Article in German | MEDLINE | ID: mdl-33491899
4.
J Dtsch Dermatol Ges ; 19(1): 31-36, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32989899

ABSTRACT

Clear cell acanthoma is a rarely diagnosed tumor with variable clinical morphology that is usually only recognized by its histopathological features. The primary lesion is a red papule a few millimeters in diameter that often occurs as a single lesion on the lower extremities. In dermoscopy, resemblance of the vessels to a string of pearls is a largely specific finding of clear cell acanthoma. In contrast to the initially uncharacteristic clinical findings, histopathology of clear cell acanthomas is characterized by a typical compact, well-demarcated acanthosis consisting of pale-staining, PAS-reactive keratinocytes. As etiology and pathogenesis are both unclear, nosology of clear cell acanthoma is also controversial, with an ongoing debate as to its classification as cutaneous neoplasia or reactive inflammatory dermatosis.


Subject(s)
Acanthoma , Keratosis , Skin Neoplasms , Dermoscopy , Humans , Keratinocytes
5.
J Dtsch Dermatol Ges ; 18(3): 199-205, 2020 Mar.
Article in German | MEDLINE | ID: mdl-32130768
6.
J Dtsch Dermatol Ges ; 18(3): 199-205, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32100965

ABSTRACT

Lymphomatoid papulosis (LyP) is characterized by a varied clinical presentation that includes erythema, papules, pustules, vesicles, plaques, nodules and ulcerations. While its biological course is typically marked by spontaneous regression, the histopathological findings of LyP are consistent with cutaneous T-cell lymphoma. Provided patients do no develop a secondary lymphoma, they exhibit unusually high 10-year survival rates (> 90 %), which is a typical feature of LyP. To date, the etiology and pathogenesis of LyP have not been elucidated. One particular subtype of LyP is known to be associated with chromosome 6p25.3 rearrangement (DUSP22-IRF4 translocation). Treatment is guided by the clinical presentation. In addition to a wait-and-see approach, recommended options include topical corticosteroids and PUVA therapy.


Subject(s)
Lymphomatoid Papulosis/pathology , Skin Neoplasms/pathology , Female , Humans , Male
7.
BMJ Open ; 9(12): e028842, 2019 12 16.
Article in English | MEDLINE | ID: mdl-31848158

ABSTRACT

OBJECTIVES: To determine whether a multicomponent sun protection intervention programme (mHealth) for young organ transplant recipients (OTR) leads to a higher increase of preventive knowledge and behavioural change than an e-learning education programme (eHealth). DESIGN: Randomised controlled trial with one preintervention baseline survey and three follow-up surveys after 6 weeks, 6 and 12 months. Comparison of two different intervention schedules with a control group (CG). SETTING: Multicomponent sun protection trainings in Germany, the Netherlands and Austria between June 2013 and September 2015. PARTICIPANTS: 137 OTRs (5-22 years of age, 61 females/76 males) participated in the study. INTERVENTIONS: (A) Intervention group 1 (IG1): personal training with subsequent forwarding of individual ultraviolet index-dependent sun protection recommendations via short message service (SMS); (B) intervention group 2 (IG2): e-learning training without SMS; (C) CG: regular information letters, online training after 1 year. OUTCOME MEASURES: Key questions were used to form a knowledge and a behavioural score. Behavioural strategies and knowledge were quantified through self-administered questionnaires. RESULTS: Analyses 6 weeks after the intervention showed a higher knowledge increase in both IG compared with the CG (IG1 to CG: OR 12.64, 95% CI 4.20 to 38.20; IG2 to CG: OR 2.59, 95% CI 0.95 to 7.04). Sun protection behaviour improved slightly but not significantly in both IG (IG1 to CG: OR 2.56, 95% CI 0.93 to 7.00; IG2 to CG: OR 1.22, 95% CI 0.45 to 3.32). One year after the intervention, no behavioural changes were observed in either IG compared with the CG. IG1 but not IG2 still scored significantly higher in sun protection knowledge than the CG 1 year after intervention (IG1 to CG: OR 4.46, 95% CI 1.48 to 13.43; IG2 to CG: OR 1.41, 95% CI 0.51 to 3.93). CONCLUSIONS: This multicomponent sun protection programme provides a promising strategy to increase sun protection knowledge and possibly also protective behaviour in young OTR. TRIAL REGISTRATION NUMBER: DRKS00011393.


Subject(s)
Health Behavior , Patient Education as Topic , Skin Neoplasms/prevention & control , Sunburn/prevention & control , Telemedicine , Text Messaging , Transplant Recipients , Adolescent , Austria , Child , Child, Preschool , Female , Germany , Health Knowledge, Attitudes, Practice , Humans , Immunosuppressive Agents/adverse effects , Logistic Models , Male , Netherlands , Organ Transplantation/adverse effects , Patient Acceptance of Health Care , Protective Factors , Skin Neoplasms/etiology , Sunburn/etiology , Surveys and Questionnaires , Time Factors , Ultraviolet Rays/adverse effects , Young Adult
10.
Acta Derm Venereol ; 96(3): 341-5, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26336924

ABSTRACT

Adolescent organ transplant recipients have an increased risk of developing skin cancer. The aim of this study was to evaluate the technical feasibility and acceptability of short messaging service-based sun protection recommendations for adolescent patients. Sun-protective knowledge and behaviour were also evaluated using standardized questionnaires and telephone interviews. Twenty-six organ transplant recipients aged 13-22 years participated in face-to-face sun protection training. Subsequently, participants received sun protection reminders via text messages for 4 weeks. Of the participants 95% reported that they checked text messages on a regular basis. Of the 26 organ transplant recipients 19 completed questionnaires before sun protection training and 4 weeks later; 16% (3/19) knew the meaning of the UV-index before training. After training, 74% (14/19) remembered that the term UV-index describes the maximum daily level of local UV radiation. Text message-based sun protection recommendations are well accepted and technically feasible in adolescent organ transplant recipients.


Subject(s)
Adolescent Behavior , Health Behavior , Health Knowledge, Attitudes, Practice , Organ Transplantation/adverse effects , Patient Education as Topic , Skin Neoplasms/prevention & control , Sunburn/prevention & control , Text Messaging , Transplant Recipients/psychology , Ultraviolet Rays/adverse effects , Adolescent , Age Factors , Austria , Feasibility Studies , Female , Germany , Humans , Immunosuppressive Agents/adverse effects , Male , Patient Acceptance of Health Care , Protective Factors , Risk Factors , Skin Neoplasms/etiology , Sunburn/etiology , Surveys and Questionnaires , Time Factors , Young Adult
15.
J Dtsch Dermatol Ges ; 11(12): 1161-7, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23937389

ABSTRACT

Cutaneous and systemic plasmacytosis is a rare disorder observed mainly in Japanese that features an infiltration of mature plasma cells in various organ systems. In addition to the skin, lymph nodes and bone marrow are regularly affected. Laboratory tests show a polyclonal hypergammaglobulinemia. The cutaneous morphology is characterized by red to dark brown macules, papules and plaques a few centimeters in diameter, usually distributed symmetrically on the face, neck and back. Etiology and pathogenesis are not known. It is speculated that a reactive dysfunction of plasma cells may be triggered by various stimuli, such as interleukin 6. Treatment of cutaneous and systemic plasmacytosis is difficult. A standardized treatment concept does not yet exist. Topical corticosteroids and calcineurin inhibitors are mainly used.


Subject(s)
Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/pathology , Lymphocytosis/diagnosis , Lymphocytosis/pathology , Plasma Cells/pathology , Skin Diseases/diagnosis , Skin Diseases/pathology , Administration, Topical , Adrenal Cortex Hormones/therapeutic use , Calcineurin Inhibitors , Dermatologic Agents/administration & dosage , Diagnosis, Differential , Humans , Hypergammaglobulinemia/drug therapy , Japan , Lymphocytosis/drug therapy , Skin Diseases/drug therapy , Treatment Outcome
16.
J Dtsch Dermatol Ges ; 11(8): 723-9, 723-30, 2013 Aug.
Article in English, German | MEDLINE | ID: mdl-23718268

ABSTRACT

Acquired reactive perforating dermatosis is characterized by umbilicated erythematous papules and plaques with firmly adherent crusts. Histopathological examination shows a typical cup-shaped ulceration in the epidermis containing cellular debris and collagen. There is transepidermal elimination of degenerated material with basophilic collagen bundles. The etiology and pathogenesis of acquired reactive perforating dermatosis are unclear. Metabolic disorders and malignancies are associated with this dermatosis. Associated pruritus is regarded as a key pathogenic factor. Constant scratching may cause a repetitive trauma to the skin. This pathogenesis may involve a genetic predisposition. The trauma may lead to degeneration of the collagen bundles. Treatment of acquired reactive perforating dermatosis follows a multimodal approach. Apart from the treating any underlying disease, treatment of pruritus is a major goal. Systemic steroids and retinoids, as well as UVB phototherapy are well-established treatment options. Some patients may also benefit from oral allopurinol.


Subject(s)
Allopurinol/therapeutic use , Collagen Diseases/diagnosis , Collagen Diseases/drug therapy , Immunosuppressive Agents/therapeutic use , Retinoids/therapeutic use , Skin Diseases, Genetic/diagnosis , Skin Diseases, Genetic/drug therapy , Steroids/therapeutic use , Ultraviolet Therapy/methods , Combined Modality Therapy , Diagnosis, Differential , Humans
18.
J Dtsch Dermatol Ges ; 11(4): 309-19, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23320493

ABSTRACT

Lichen planus is characterized by lichenoid, polygonal papules with fine white lines, called Wickham striae. Lesions most commonly occur on the limbs and on the dorsal aspect of the trunk. At the same time often leukoplakia of mucous membranes as well as nail disorders are seen. There are numerous variants of lichen planus which can be distinguished from the classical form on the basis of morphology and distribution of the lesions. The typical primary lesion of lichen planus may be replaced by other forms, such as patches, hyperkeratoses, ulcerations, or bullous lesions. Moreover, distribution patterns of these lesions may vary and include erythrodermic, inverse or linear arrangements. In contrast to these numerous clinical features, histologic findings remain characteristic in the variants, so that the diagnosis can be made securely. Differential diagnoses of lichen planus include diverse dermatoses such as bullous pemphigoid or paronychia.


Subject(s)
Lichen Planus/classification , Lichen Planus/diagnosis , Diagnosis, Differential , Humans
20.
J Dtsch Dermatol Ges ; 10(4): 238-44, 2012 Apr.
Article in English, German | MEDLINE | ID: mdl-22429645

ABSTRACT

Ramsay Hunt syndrome is defined as herpes zoster oticus associated with an acute peripheral facial nerve paresis and quite often with other cranial nerve lesions. The combination of motor, sensory and autonomic involvement leads to a variety of neurological damage patterns, i. e. facial muscle paresis, hearing and balance disorders, sensory problems and disturbances of taste as well as lacrimal and nasal secretion. Additional variability of the clinical picture of Ramsay Hunt syndrome is produced by varying patterns of skin involvement explained by individual anastomoses between cranial and cervical nerves. Knowledge of these findings and an early diagnosis of Ramsay Hunt syndrome are important as prognosis of cranial nerve damage depends on the time at which acyclovir-corticosteroid therapy is started.


Subject(s)
Acyclovir/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Herpes Zoster Oticus/diagnosis , Herpes Zoster Oticus/drug therapy , Antiviral Agents/therapeutic use , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...